Artiva Biotherapeutics launches Phase 3 trial of AlloNK plus rituximab in refractory rheumatoid arthritis

Artiva Biotherapeutics launches Phase 3 trial of AlloNK plus rituximab in refractory rheumatoid arthritis.

Artiva outlined second-half 2026 data disclosures for AlloNK with rituximab in its Phase 2a autoimmune basket trial. Updated readouts are expected, not yet presented, with follow-up from refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis cohorts.

The company plans to start a Phase 3 registrational trial in refractory rheumatoid arthritis, comparing AlloNK with rituximab against rituximab alone.

Management framed earlier rheumatoid arthritis results as encouraging, citing favorable activity with no major safety signals reported to date. Topline Phase 3 results are targeted by end-2028, a key value inflection point for the program’s regulatory path.